The GENERATION HD2 clinical trial is just about to start recruiting participants in the first of a total of 15 countries and 9 of them are in Europe: Denmark, France, Germany, UK, Poland, Italy, Spain, Portugal and Switzerland. The study aims to enroll 360 participants and evaluate the safety of the investigational drug tominersen in people with early manifest HD.
👥 The Clinical Science Leader from Roche, Dr. Peter McColgan, and the Principal Investigator in Madrid (Spain), Dr. José Luis López-Sendón, will provide the latest updates of the study and their research efforts in HD. After the presentations, there will be time for comments and questions.
🙌 We hope everyone will take this opportunity to learn more about Roche research efforts on Huntington’s Disease.